Speakers:

Rajat Bannerji, MD, PhD, Rutgers Cancer Institute of New Jersey

Dennis Cooper, MD, Rutgers Cancer Institute of New Jersey

Kevin David, MD, Rutgers Cancer Institute of New Jersey

Andrew M. Evens, DO, MSc, FACP, Rutgers Cancer Institute of New Jersey

Athena Kritharis, MD, Rutgers Cancer Institute of New Jersey

Vimal Patel, MD, Rutgers Cancer Institute of New Jersey

Dale Schaar, MD, PhD, Rutgers Cancer Institute of New Jersey

Roger Strair, MD, PhD, Rutgers Cancer Institute of New Jersey

Goal: To provide an overview of new targeted therapies in hematologic malignancies as well as the efficacy for CAR T-cell therapy and transplant.

Objectives: At the conclusion of this in-person program, participants will be able to:

· Describe new targeted therapies for non-Hodgkin lymphoma and Hodgkin’s disease

· Explain treatment algorithms for patients with advanced myeloid malignancies

· Discuss new treatment options and paradigms for Chronic Lymphocytic Leukemia

· Identify the selection of patients and therapeutic efficacy for CAR T-cell therapy and transplant

· Discuss resources available including those from LLS for patients, caregivers and healthcare providers

Target Audience: Oncology physicians, nurses and nurse practitioners at all levels of experience and licensure, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.

Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 2.5 continuing education contact hours through the California Board of Registered Nursing.

Upon completion of this program and submission of the activity evaluation, a certificate of completion will be emailed to you within 30 days.